Base de dados : MEDLINE
Pesquisa : G12.300 [Categoria DeCS]
Referências encontradas : 11923 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1193 ir para página                         

  1 / 11923 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27775991
[Au] Autor:Kan B; Yang L; Wen YJ; Yang JR; Niu T; Li J; Deng HX; Wei W; Chen LG; Zhang Q; Wang W; Wei YQ
[Ad] Endereço:aState Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy bDepartment of Emergency, West China Hospital, Sichuan University, Chengdu cSchool of Pharmaceutical Sciences, Tsinghua University, Beijing dState Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Nankai University, Tianjin, People's Republic of China.
[Ti] Título:Irradiated VEGF164-modified tumor cell vaccine protected mice from the parental tumor challenge.
[So] Source:Anticancer Drugs;28(2):197-205, 2017 02.
[Is] ISSN:1473-5741
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Vascular endothelial growth factor (VEGF) is an important regulating molecule of angiogenesis in tumor formation and progression. Cancer cells always secrete VEGF to stimulate angiogenesis that facilitate growth and invasion of the tumor. In this study, we established a VEGF164 overexpressing LL/2 lung cancer cell model and found that the postirradiated VEGF164-modified tumor cells protected the host against the challenge with LL/2 wild-type tumor cells. Histochemical assay showed that there were large areas of tumor necrosis with macrophage infiltration in the mice vaccinated with the VEGF164-modified tumor vaccine. T-cells isolated from the vaccinated mice showed cytotoxicity against the parental tumor cells in a dose-dependent manner. Meanwhile, sera from the mice vaccinated with LL/2-VEGF164 showed higher titers of antibodies against parental tumor cells compared with the nonvaccinated groups. Our results indicated that VEGF164-modified tumor vaccine could modulate host antitumor immune response and hold therapeutic potential for cancer.
[Mh] Termos MeSH primário: Vacinas Anticâncer/imunologia
Imunoterapia Adotiva/métodos
Neoplasias Pulmonares/imunologia
Neoplasias Pulmonares/terapia
Fator A de Crescimento do Endotélio Vascular/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Linfócitos T CD4-Positivos/imunologia
Linfócitos T CD8-Positivos/imunologia
Vacinas Anticâncer/genética
Relação Dose-Resposta Imunológica
Feminino
Neoplasias Pulmonares/genética
Neoplasias Pulmonares/metabolismo
Camundongos
Camundongos Endogâmicos C57BL
Linfócitos T Citotóxicos/imunologia
Transfecção
Fator A de Crescimento do Endotélio Vascular/biossíntese
Fator A de Crescimento do Endotélio Vascular/genética
Fator A de Crescimento do Endotélio Vascular/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cancer Vaccines); 0 (Vascular Endothelial Growth Factor A); 0 (vascular endothelial growth factor A, mouse)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1097/CAD.0000000000000447


  2 / 11923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29254303
[Au] Autor:Abbasi MH; Fatima S; Khawar MB; Naz N; Mujeeb KA; Akhtar T; Sheikh N
[Ad] Endereço:Department of Zoology, Government College of Science, Lahore, Pakistan.
[Ti] Título:Dose-dependent acute phase response of aqueous leaf decoction of Nerium oleander in Wistar rats.
[So] Source:J Biol Regul Homeost Agents;31(4):985-989, 2017 Oct-Dec.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Many studies have been carried out in order to determine the toxicity of medicinal plants. The objective of this study was to compare and analyze the hepatic response against two doses of Nerium oleander, (N. oleander) “kaner” leaf decoction. Aqueous leaf decoction was injected intramuscularly into both hind limbs of male rats (200∓10g), assigned into three categories (n=4): control group with no treatment; group I, injected with 5 ml/ kg; and group II injected with 10 ml/ kg of leaf decoction, respectively. Animals were sacrificed 6 h after administration and hepato-histological changes were then observed. The decoction induced an acute phase reaction reflected by a more significant recruitment of inflammatory cells in group II than in group I and controls, as observed by histological studies. These results indicated that both doses can induce an acute-phase condition. Hence, traditional practice of medicinal plants without preliminary dose assessment must not be administered.
[Mh] Termos MeSH primário: Reação de Fase Aguda/induzido quimicamente
Fígado/efeitos dos fármacos
Nerium/química
Extratos Vegetais/efeitos adversos
Folhas de Planta/química
[Mh] Termos MeSH secundário: Reação de Fase Aguda/imunologia
Reação de Fase Aguda/patologia
Animais
Biomarcadores/metabolismo
Relação Dose-Resposta Imunológica
Ectodisplasinas/imunologia
Ectodisplasinas/metabolismo
Imuno-Histoquímica
Injeções Intramusculares
Fígado/imunologia
Fígado/patologia
Masculino
Plantas Medicinais
Ratos
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Ectodysplasins); 0 (Plant Extracts)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  3 / 11923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29267298
[Au] Autor:Ikegami T; Balogh A; Nishiyama S; Lokugamage N; Saito TB; Morrill JC; Shivanna V; Indran SV; Zhang L; Smith JK; Perez D; Juelich TL; Morozov I; Wilson WC; Freiberg AN; Richt JA
[Ad] Endereço:Department of Pathology, The University of Texas Medical Branch, Galveston, Texas, United States of America.
[Ti] Título:Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages in a mouse model.
[So] Source:PLoS One;12(12):e0189250, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Rift Valley fever phlebovirus (RVFV) causes high rates of abortions and fetal malformations in ruminants, and hemorrhagic fever, encephalitis, or blindness in humans. Viral transmission occurs via mosquito vectors in endemic areas, which necessitates regular vaccination of susceptible livestock animals to prevent the RVF outbreaks. Although ZH501 strain has been used as a challenge strain for past vaccine efficacy studies, further characterization of other RVFV strains is important to optimize ruminant and nonhuman primate RVFV challenge models. This study aimed to characterize the virulence of wild-type RVFV strains belonging to different genetic lineages in outbred CD1 mice. Mice were intraperitoneally infected with 1x103 PFU of wild-type ZH501, Kenya 9800523, Kenya 90058, Saudi Arabia 200010911, OS1, OS7, SA75, Entebbe, or SA51 strains. Among them, mice infected with SA51, Entebbe, or OS7 strain showed rapid dissemination of virus in livers and peracute necrotic hepatitis at 2-3 dpi. Recombinant SA51 (rSA51) and Zinga (rZinga) strains were recovered by reverse genetics, and their virulence was also tested in CD1 mice. The rSA51 strain reproduced peracute RVF disease in mice, whereas the rZinga strain showed a similar virulence with that of rZH501 strain. This study showed that RVFV strains in different genetic lineages display distinct virulence in outbred mice. Importantly, since wild-type RVFV strains contain defective-interfering RNA or various genetic subpopulations during passage from original viral isolations, recombinant RVFV strains generated by reverse genetics will be better suitable for reproducible challenge studies for vaccine development as well as pathological studies.
[Mh] Termos MeSH primário: Modelos Animais de Doenças
Vírus da Febre do Vale do Rift/patogenicidade
Virulência/genética
[Mh] Termos MeSH secundário: Animais
Linhagem Celular
Relação Dose-Resposta Imunológica
Feminino
Fígado/patologia
Camundongos
Vírus da Febre do Vale do Rift/genética
Vírus da Febre do Vale do Rift/imunologia
Inoculações Seriadas
Baço/patologia
Vacinas Virais/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Viral Vaccines)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189250


  4 / 11923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27775867
[Au] Autor:Fischer J; Eberlein B; Hilger C; Eyer F; Eyerich S; Ollert M; Biedermann T
[Ad] Endereço:Department of Dermatology, Faculty of Medicine, Eberhard Karls University Tuebingen, Tuebingen, Germany.
[Ti] Título:Alpha-gal is a possible target of IgE-mediated reactivity to antivenom.
[So] Source:Allergy;72(5):764-771, 2017 May.
[Is] ISSN:1398-9995
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Antivenoms are mammalian immunoglobulins with the ability to neutralize snake venom components and to mitigate the progression of toxic effects. Immediate hypersensitivity to antivenoms often occurs during the first administration of these heterologous antibodies. A comparable clinical situation occurred after introduction of cetuximab, a chimeric mouse-human antibody, for cancer treatment. The carbohydrate epitope galactose-alpha-1,3-galactose, located on the Fab region of cetuximab, was identified as the target responsible for IgE reactivity. OBJECTIVE: To investigate whether serum IgE antibodies directed to the α-gal epitope are associated with hypersensitivity to equine antivenoms. METHODS: Antivenoms were screened for α-gal epitopes via immunoblot and in comparison with cetuximab and pork kidney by IgE reactivity assays. Basophil activation tests were used to investigate reactivity to antivenoms in samples from 20 patients with specific IgE antibodies to α-gal and 10 controls. Additional IgE detection, IgE inhibition, ImmunoCAP inhibition, and skin prick tests were performed using samples from selected patients. RESULTS: Both antivenoms and cetuximab induced positive skin prick test results in patients with sIgE to α-gal. Alpha-gal epitopes were detected by immunoblotting on antivenoms. Measurements of IgE reactivity and ImmunoCAP inhibition indicated that the antivenoms contained lower α-gal contents than cetuximab. Deglycosylation assays and IgE inhibition tests confirmed that IgE-mediated reactivity to antivenom is associated with α-gal. Antivenoms, pork kidney, and cetuximab activated basophils from patients with IgE to α-gal. CONCLUSION: Alpha-gal is a potential target of IgE-mediated reactivity to equine antivenom and a possible cause of the high incidence of hypersensitivity reactions during the first application of equine antivenom.
[Mh] Termos MeSH primário: Antivenenos/imunologia
Hipersensibilidade Imediata/imunologia
Imunoglobulina E/imunologia
alfa-Galactosidase/imunologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Animais
Basófilos/imunologia
Basófilos/metabolismo
Biomarcadores
Cetuximab/efeitos adversos
Relação Dose-Resposta Imunológica
Epitopos/imunologia
Feminino
Cavalos
Seres Humanos
Hipersensibilidade Imediata/diagnóstico
Hipersensibilidade Imediata/metabolismo
Masculino
Meia-Idade
Testes Cutâneos
Tetraspanina 30/metabolismo
Tireoglobulina/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antivenins); 0 (Biomarkers); 0 (Epitopes); 0 (Tetraspanin 30); 37341-29-0 (Immunoglobulin E); 9010-34-8 (Thyroglobulin); EC 3.2.1.22 (alpha-Galactosidase); PQX0D8J21J (Cetuximab)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171207
[Lr] Data última revisão:
171207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1111/all.13073


  5 / 11923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29023507
[Au] Autor:Sordé L; Spindeldreher S; Palmer E; Karle A
[Ad] Endereço:Novartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Basel, Switzerland.
[Ti] Título:Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?
[So] Source:PLoS One;12(10):e0186046, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Administration of high dose intravenous immunoglobulin (IVIg) is widely used in the clinic to treat autoimmune and severe inflammatory diseases. However, its mechanisms of action remain poorly understood. We assessed the impact of IVIg on immune cell populations using an in vivo ovalbumin (Ova)-immunization mouse model. High dose IVIg significantly reduced the Ova-specific antibody response. Intriguingly, the results obtained indicate an immediate and massive immune reaction against IVIg, as shown by the activation and expansion of B cells and CD4+ T cells in the spleen and draining lymph nodes and the production of IVIg-specific antibodies. We propose that IVIg competes at the T-cell level with the response against Ova to explain the immunomodulatory properties of IVIg. Two monoclonal antibodies did not succeeded in reproducing the effects of IVIg. This suggests that in addition to the mouse response against human constant domains, the enormous sequence diversity of IVIg may significantly contribute to this massive immune response against IVIg. While correlation of these findings to IVIg-treated patients remains to be explored, our data demonstrate for the first time that IVIg re-directs the immune response towards IVIg and away from a specific antigen response.
[Mh] Termos MeSH primário: Formação de Anticorpos/imunologia
Imunoglobulinas Intravenosas/imunologia
Ovalbumina/imunologia
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/farmacologia
Animais
Anticorpos Monoclonais/imunologia
Anticorpos Monoclonais/farmacologia
Formação de Anticorpos/efeitos dos fármacos
Antígenos/imunologia
Linfócitos B/imunologia
Bevacizumab/imunologia
Bevacizumab/farmacologia
Linfócitos T CD4-Positivos/imunologia
Relação Dose-Resposta Imunológica
Epitopos/imunologia
Feminino
Seres Humanos
Imunoglobulinas Intravenosas/administração & dosagem
Linfonodos/efeitos dos fármacos
Linfonodos/imunologia
Camundongos Endogâmicos C57BL
Baço/efeitos dos fármacos
Baço/imunologia
Timo/efeitos dos fármacos
Timo/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Monoclonal); 0 (Antigens); 0 (Epitopes); 0 (Immunoglobulins, Intravenous); 2S9ZZM9Q9V (Bevacizumab); 9006-59-1 (Ovalbumin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171013
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186046


  6 / 11923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29020069
[Au] Autor:Billard MN; De Serres G; Gariépy MC; Boulianne N; Toth E; Landry M; Skowronski DM
[Ad] Endereço:Centre de recherche du CHU de Québec-Université Laval, Quebec City, QC, Canada.
[Ti] Título:Prevalence of risk factors for acquiring measles during the 2011 outbreak in Quebec and impact of the province-wide school-based vaccination campaign on population immunity.
[So] Source:PLoS One;12(10):e0186070, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A large measles outbreak occurred in Quebec, Canada, in 2011. Although nearly two-thirds of the cases occurred in only two health districts, a mass vaccination campaign targeting all Quebec elementary and high school students without valid two-dose history was undertaken to prevent future outbreaks. We compared rates of non-vaccination and age at first measles vaccine dose among students in the two most-affected districts and the rest of the province and estimated the improvement in overall student measles immunity due to the mass school-based vaccination campaign. METHODS: Data were extracted from the provincial vaccination registry for students in kindergarten to grade 11 during the 2011/2012 school year. A telephone survey was conducted in three sub-groups: students whose first measles vaccine dose recorded in the vaccination registry was received during the 2011 school vaccination campaign; students with no dose recorded in the registry whose parents refused receipt during the school campaign; and students with no dose recorded in the registry and no information about parental consent/refusal during the school campaign. RESULTS: Neither the prevalence of being non-vaccinated nor a younger age at first pediatric dose were higher in the two most-affected districts versus the rest of the province. The school campaign vaccinated nearly 8% of all students including 7% who previously received at least one dose. Before the outbreak, 3% of students were not vaccinated and one-third of these (1%/3%) were vaccinated during the campaign. The campaign likely increased the absolute school population immunity by just 1.7%. CONCLUSION: The concentration of measles cases in the two most-affected health districts during the large Quebec outbreak is not explained by more students who were unvaccinated or who had received their first vaccine dose at a younger age. The vaccination campaign reached one-third of unvaccinated students and only marginally improved population immunity.
[Mh] Termos MeSH primário: Surtos de Doenças/estatística & dados numéricos
Imunidade
Vacinação em Massa/estatística & dados numéricos
Vacina contra Sarampo/imunologia
Sarampo/epidemiologia
Sarampo/imunologia
Instituições Acadêmicas/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Criança
Relação Dose-Resposta Imunológica
Seres Humanos
Prevalência
Quebeque/epidemiologia
Fatores de Risco
Estudantes/estatística & dados numéricos
Inquéritos e Questionários
Telefone
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Measles Vaccine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171012
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186070


  7 / 11923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28904191
[Au] Autor:Littwitz-Salomon E; Schimmer S; Dittmer U
[Ad] Endereço:Institute for Virology of the University Hospital Essen, University of Duisburg-Essen, Essen, Germany Elisabeth.Littwitz@uni-due.de.
[Ti] Título:Dose of Retroviral Infection Determines Induction of Antiviral NK Cell Responses.
[So] Source:J Virol;91(22), 2017 Nov 15.
[Is] ISSN:1098-5514
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Natural killer (NK) cells are part of the innate immune system and recognize virus-infected cells as well as tumor cells. Conflicting data about the beneficial or even detrimental role of NK cells in different infectious diseases have been described previously. While the type of pathogen strongly influences NK cell functionality, less is known about how the infection dose influences the quality of a NK cell response against retroviruses. In this study, we used the well-established Friend retrovirus (FV) mouse model to investigate the impact of virus dose on the induction of antiviral NK cell functions. High-dose virus inoculation increased initial virus replication compared to that with medium- or low-dose viral challenge and significantly improved NK cell activation. Antiviral NK cell activity, including cytotoxicity toward infected target cells, was also enhanced by high-dose virus infection. NK cell activation following high-dose viral challenge was likely mediated by activated dendritic cells (DCs) and macrophages and the NK cell-stimulating cytokines interleukin 15 (IL-15) and IL-18. Neutralization of these cytokines decreased NK cell functions and increased viral loads, whereas IL-15 and IL-18 therapy improved NK cell activity. Here we demonstrate that virus dose positively correlates with antiviral NK cell activity and function, which are at least partly driven by IL-15 and IL-18. Our results suggest that NK cell activity may be therapeutically enhanced by administering IL-15 and IL-18 in virus infections that inadequately activate NK cells. In infections with retroviruses, like HIV and FV infection of mice, NK cells clearly mediate antiviral activities, but they are usually not sufficient to prevent severe pathology. Here we show that the initial infection dose impacts the induction of an antiviral NK cell response during an acute retroviral infection, which had not investigated before. High-dose infection resulted in a strong NK cell functionality, whereas no antiviral activities were detected after low- or medium-dose infection. Interestingly, DCs and macrophages were highly activated after high-dose FV challenge, which corresponded with increased levels of NK cell-stimulating cytokines IL-15 and IL-18. IL-15 and IL-18 neutralization decreased NK cell functions, whereas IL-15 and IL-18 therapy improved NK cell activity. Here we show the importance of cytokines for NK cell activation in retroviral infections; our findings suggest that immunotherapy combining the well-tolerated cytokines IL-15 and IL-18 might be an interesting approach for antiretroviral treatment.
[Mh] Termos MeSH primário: Vírus da Leucemia Murina de Friend/imunologia
Células Matadoras Naturais/imunologia
Ativação Linfocitária
Infecções por Retroviridae/imunologia
[Mh] Termos MeSH secundário: Animais
Relação Dose-Resposta Imunológica
Feminino
Interleucina-15/imunologia
Interleucina-15/farmacologia
Interleucina-18/imunologia
Interleucina-18/farmacologia
Camundongos
Infecções por Retroviridae/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Interleukin-15); 0 (Interleukin-18)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170915
[St] Status:MEDLINE


  8 / 11923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28847868
[Au] Autor:Gerner MY; Casey KA; Kastenmuller W; Germain RN
[Ad] Endereço:Department of Immunology, University of Washington, Seattle, WA gernermy@uw.edu.
[Ti] Título:Dendritic cell and antigen dispersal landscapes regulate T cell immunity.
[So] Source:J Exp Med;214(10):3105-3122, 2017 Oct 02.
[Is] ISSN:1540-9538
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Dendritic cell (DC) subsets with biased capacity for CD4 and CD8 T cell activation are asymmetrically distributed in lymph nodes (LNs), but how this affects adaptive responses has not been extensively studied. Here we used quantitative imaging to examine the relationships among antigen dispersal, DC positioning, and T cell activation after protein immunization. Antigens rapidly drained into LNs and formed gradients extending from the lymphatic sinuses, with reduced abundance in the deep LN paracortex. Differential localization of DCs specialized for major histocompatibility complex I (MHC I) and MHC II presentation resulted in preferential activation of CD8 and CD4 T cells within distinct LN regions. Because MHC I-specialized DCs are positioned in regions with limited antigen delivery, modest reductions in antigen dose led to a substantially greater decline in CD8 compared with CD4 T cell activation, expansion, and clonal diversity. Thus, the collective action of antigen dispersal and DC positioning regulates the extent and quality of T cell immunity, with important implications for vaccine design.
[Mh] Termos MeSH primário: Células Dendríticas/fisiologia
Linfócitos T/imunologia
[Mh] Termos MeSH secundário: Animais
Antígenos/imunologia
Linfócitos T CD4-Positivos/imunologia
Linfócitos T CD4-Positivos/fisiologia
Linfócitos T CD8-Positivos/imunologia
Linfócitos T CD8-Positivos/fisiologia
Células Dendríticas/imunologia
Relação Dose-Resposta Imunológica
Feminino
Imunidade Celular
Ativação Linfocitária
Complexo Principal de Histocompatibilidade/imunologia
Complexo Principal de Histocompatibilidade/fisiologia
Masculino
Camundongos
Camundongos Transgênicos
Linfócitos T/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; VIDEO-AUDIO MEDIA
[Nm] Nome de substância:
0 (Antigens)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170830
[St] Status:MEDLINE
[do] DOI:10.1084/jem.20170335


  9 / 11923 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28841693
[Au] Autor:Zhang A; Wang D; Li J; Gao F; Fan X
[Ad] Endereço:Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, College of Life Science and Technology, Xinjiang University, Urumqi, China.
[Ti] Título:The effect of aqueous extract of Xinjiang Artemisia rupestris L. (an influenza virus vaccine adjuvant) on enhancing immune responses and reducing antigen dose required for immunity.
[So] Source:PLoS One;12(8):e0183720, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Potent adjuvant can improve the effectiveness of vaccines and reduce the antigen doses required for initiating the protective immunity. In this study, we identified that aqueous extract of Artemisia rupestris L. (AEAR) could be employed as an efficient adjuvant for influenza virus vaccine (V) to enhance immune responses and reduce the antigen doses required for initiating immunity, without compromising the immune response. ICR mice were subcutaneously co-administrated with V combined with different concentrations of AEAR demonstrated that 300 µg AEAR could significantly improve hemagglutination inhibition (HI) and increase IgG antibody titers in serum (P<0.05) and the population of CD4+CD44+ and CD8+CD44+ (P<0.05). Next, 300 µg AEAR combined with different doses of V in vivo markedly increased HI and specific IgG antibody level(P<0.05). It also significantly increased the amount of CD4+ and CD8+ T cells, CD4+CD44+ and CD8+CD44+ T cells (P<0.05), improved lymphocyte proliferation, the secretion of CD4+IL-4, CD4+IFN-γ and CD8+IFN-γ (P<0.05), and the killing efficacy of cytotoxic T lymphocyte (CTL) (P<0.05). Furthermore, the combination increased the expression of major histocompatibility complex-II (MHC-II) and co-stimulatory molecules including CD40, CD80, and CD86 on dendritic cells (DCs), and downregulated the expression of CD25+Foxp3+Treg cells (P<0.05). No significant difference was observed between high-dose V and low-dose AEAR-V (10-fold lower) vaccination group (P>0.05), indicating a 10-fold reduction of antigen required for V vaccine administration. In conclusion, this study demonstrated that AEAR, as an adjuvant for influenza vaccine, could stimulate potent humoral and cellular immune responses and reduce the antigen dose required for effective vaccination, which were mediated by promoting DCs activation and repressing Treg expression.
[Mh] Termos MeSH primário: Adjuvantes Imunológicos/farmacologia
Antígenos/administração & dosagem
Artemisia/química
Extratos Vegetais/farmacologia
[Mh] Termos MeSH secundário: Proliferação Celular
Citocinas/metabolismo
Citotoxicidade Imunológica
Relação Dose-Resposta Imunológica
Ensaio de Imunoadsorção Enzimática
Imunoglobulina G/sangue
Linfócitos T/citologia
Linfócitos T/imunologia
Água
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antigens); 0 (Cytokines); 0 (Immunoglobulin G); 0 (Plant Extracts); 059QF0KO0R (Water)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170826
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183720


  10 / 11923 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28806737
[Au] Autor:Domínguez Á; Ciruela P; Hernández S; García-García JJ; Soldevila N; Izquierdo C; Moraga-Llop F; Díaz A; F de Sevilla M; González-Peris S; Campins M; Uriona S; Martínez-Osorio J; Solé-Ribalta A; Codina G; Esteva C; Planes AM; Muñoz-Almagro C; Salleras L
[Ad] Endereço:Departament de Medicina, Universitat de Barcelona, Barcelona, Spain.
[Ti] Título:Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. A matched case-control study.
[So] Source:PLoS One;12(8):e0183191, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The 13-valent pneumococcal conjugate vaccine (PCV13) was licensed based on the results of immunogenicity studies and correlates of protection derived from randomized clinical trials of the 7-valent conjugate pneumococcal vaccine. We assessed the vaccination effectiveness (VE) of the PCV13 in preventing invasive pneumococcal disease (IPD) in children aged 7-59 months in a population with suboptimal vaccination coverage of 55%. METHODS: The study was carried out in children with IPD admitted to three hospitals in Barcelona (Spain) and controls matched by hospital, age, sex, date of hospitalization and underlying disease. Information on the vaccination status was obtained from written medical records. Conditional logistic regression was made to estimate the adjusted VE and 95% confidence intervals (CI). RESULTS: 169 cases and 645 controls were included. The overall VE of ≥1 doses of PCV13 in preventing IPD due to vaccine serotypes was 75.8% (95% CI, 54.1-87.2) and 90% (95% CI, 63.9-97.2) when ≥2 doses before 12 months, two doses on or after 12 months or one dose on or after 24 months, were administered. The VE of ≥1 doses was 89% (95% CI, 42.7-97.9) against serotype 1 and 86.0% (95% CI, 51.2-99.7) against serotype 19A. Serotype 3 showed a non-statistically significant effectiveness (25.9%; 95% CI, -65.3 to 66.8). CONCLUSIONS: The effectiveness of ≥1 doses of PCV13 in preventing IPD caused by all PCV13 serotypes in children aged 7-59 months was good and, except for serotype 3, the effectiveness of ≥1 doses against the most frequent PCV13 serotypes causing IPD was high when considered individually.
[Mh] Termos MeSH primário: Infecções Pneumocócicas/imunologia
Infecções Pneumocócicas/prevenção & controle
Vacinas Pneumocócicas/imunologia
Vacinas Conjugadas/imunologia
[Mh] Termos MeSH secundário: Estudos de Casos e Controles
Criança
Pré-Escolar
Relação Dose-Resposta Imunológica
Feminino
Vacina Pneumocócica Conjugada Heptavalente/imunologia
Seres Humanos
Lactente
Masculino
Sorogrupo
Resultado do Tratamento
Vacinação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (13-valent pneumococcal vaccine); 0 (Heptavalent Pneumococcal Conjugate Vaccine); 0 (Pneumococcal Vaccines); 0 (Vaccines, Conjugate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171009
[Lr] Data última revisão:
171009
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183191



página 1 de 1193 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde